Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects. [PDF]
Zong Y, Fan Q, Huang L.
europepmc +1 more source
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). [PDF]
Gilbert Farrar K +4 more
europepmc +1 more source
Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake. [PDF]
Rieger C +4 more
europepmc +1 more source
Effectiveness and Safety Outcomes After Switching from Reference Biologics to Biosimilars for Treatment of Non-Infectious Uveitis: A Systematic Review and Meta-Analysis. [PDF]
Felfeli T +8 more
europepmc +1 more source
Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? [PDF]
Burton E +7 more
europepmc +1 more source
From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development. [PDF]
Ribes S +4 more
europepmc +1 more source
Impact of Regional Healthcare Policy Interventions on Biosimilar Use: A 10-year Evaluation of TNFα Inhibitors Utilization in Italy. [PDF]
Vitturi G +40 more
europepmc +1 more source
Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: <i>A Clinical Experience</i>. [PDF]
Najjar RH +5 more
europepmc +1 more source
Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany. [PDF]
Kaufhold I +4 more
europepmc +1 more source

